Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Biotech companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field., part of AlfasigmaLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record.
As of Nov 21, 2026, FDA's public records list Intercept Pharmaceuticals with 2 drug applications. The most recent is a drug application dated Mar 17, 2026: Lynavoy.
Drug applications: 2
Records by year
Drug approvals, 510(k) clearances, recalls and letters, 2026 to date
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
120262026 to dateRecords1
Latest records
Newest first across sources; each opens the record
6 trials since 2013, 0 ongoing, by the sponsor of the products; see every authorized trial
A phase 3, open-label, long-term safety extension study evaluating the safety and tolerability of the fixed-dose…Jun 4, 2024 · Closed · Obeticholic acid-bezafibrate
A randomized, double-blind, placebo-controlled, phase 2/3 study to assess the efficacy, safety, tolerability,…Feb 7, 2024 · Closed · Obeticholic acid
A phase 2a, double-blind, randomized, active controlled, parallel group study evaluating the efficacy, safety, and…Mar 25, 2022 · Closed · Obeticholic acid / Bezafibrate
A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of…May 2, 2018 · Closed · Obeticholic acid
A phase 3, double-blind, randomized, long-term, placebo-controlled, multicenter study evaluating the safety and…Nov 10, 2015 · Closed · Obeticholic acid (INT-747)
A phase 3b, double blind, randomized, placebo controlled, multicenter study evaluating the effect of obeticholic acid…Jul 21, 2015 · Closed · Obeticholic acid (INT-747)
Payments to doctors (Open Payments)
What this company reported paying US doctors and teaching hospitals each year, $97.3M of it for research; see every company
$34.0M20192019Paid$34.0M
$21.1M20202020Paid$21.1Mvs 2019−$13.0M
$23.1M20212021Paid$23.1Mvs 2020+$2.0M
$17.9M20222022Paid$17.9Mvs 2021−$5.2M
$13.9M20232023Paid$13.9Mvs 2022−$4.0M
$5.1M20242024Paid$5.1Mvs 2023−$8.7M
$2.6M20252025Paid$2.6Mvs 2024−$2.5M
Orphan designations (FDA)
4 designations since 1983, 2 approved for the designated use, matched by the sponsor's name; see all orphan designations
OcalivaTreatment of primary biliary cirrhosis · Apr 9, 2008 · approved May 27, 2016
Names and identifiers
Appears as
INTERCEPT
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.